These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 23513884)

  • 41. Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?
    Mandalà M; Moro C; Labianca R; Ferretti G
    J Clin Oncol; 2007 Sep; 25(27):4320-1; author reply 4321-2. PubMed ID: 17878488
    [No Abstract]   [Full Text] [Related]  

  • 42. Perspectives in central nervous system malignancies.
    Stummer W
    IDrugs; 2006 Jun; 9(6):412-4. PubMed ID: 16752310
    [No Abstract]   [Full Text] [Related]  

  • 43. [Report from a small registry-permetrexed, tarceva and yondelis].
    Pochop L; Hejduk K
    Klin Onkol; 2013; 26(1):53-4. PubMed ID: 23607142
    [No Abstract]   [Full Text] [Related]  

  • 44. [Pancreatic carcinoma].
    Okamoto T; Onda S
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():463-7. PubMed ID: 23513884
    [No Abstract]   [Full Text] [Related]  

  • 45. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
    Chang BW; Saif MW
    JOP; 2009 May; 10(3):231-6. PubMed ID: 19454812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
    Welch SA; Moore MJ
    Future Oncol; 2007 Jun; 3(3):247-54. PubMed ID: 17547518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?
    Laurent-Puig P; Taieb J
    Curr Opin Oncol; 2008 Jul; 20(4):454-8. PubMed ID: 18525343
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Neuroendocrine tumors: the age of targeted therapies].
    Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
    Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
    Wolin EM
    Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.
    Prescrire Int; 2012 Oct; 21(131):234. PubMed ID: 23185844
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting mTOR in mantle cell lymphoma: current and future directions.
    Smith SM
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Progress of molecularly targeted therapy for breast cancer].
    Ito Y
    Rinsho Ketsueki; 2012 Apr; 53(4):426-32. PubMed ID: 22687976
    [No Abstract]   [Full Text] [Related]  

  • 53. Mammalian target of rapamycin as a target in hematological malignancies.
    Abdel-Karim IA; Giles FJ
    Curr Probl Cancer; 2008; 32(4):161-77. PubMed ID: 18655914
    [No Abstract]   [Full Text] [Related]  

  • 54. Targeted therapy for lung cancer.
    Petrosyan F; Daw H; Haddad A; Spiro T
    Anticancer Drugs; 2012 Nov; 23(10):1016-21. PubMed ID: 22932130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.
    Wiedenmann B; Pavel M; Kos-Kudla B
    Neuroendocrinology; 2011; 94(3):177-90. PubMed ID: 21893937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 57. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.